Overview

Study of VESIcare® In Overactive Bladder (OAB) Subjects to Evaluate Symptom Bother and Health Related Quality of Life

Status:
Completed
Trial end date:
2008-07-01
Target enrollment:
Participant gender:
Summary
Evaluate the effect of VESIcare® on symptom bother for subjects with OAB
Phase:
Phase 4
Details
Lead Sponsor:
Astellas Pharma Inc
Treatments:
Solifenacin Succinate